Back to All Combinations

EGFR S492R

Intermediate Prognosis
2.00% Prevalence Level 2B Resistance Mechanisms
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
EGFR
Treatment Implications

Blocks cetuximab but panitumumab still binds.

Recommended Treatments
Switch to Panitumumab
Treatments to Avoid
Continue Cetuximab
Study References

Montagut et al

Key Statistics
2.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
S492R = cetuximab-specific resistance.
Information

Category: Resistance Mechanisms

Evidence Level: Level 2B

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.